GlaxoSmithKline PLC Moncef Slaoui Departs Galvani Bioelectronics (3599T)
2021年3月24日 - 9:30PM
RNSを含む英国規制内ニュース (英語)
TIDMGSK
RNS Number : 3599T
GlaxoSmithKline PLC
24 March 2021
Issued: 24 March 2021, London UK
Moncef Slaoui Departs Galvani Bioelectronics Board of
Directors
The Board of Directors of GlaxoSmithKline plc ("GSK"), the
majority shareholder of Galvani Bioelectronics ("Galvani"), today
announced the termination of Moncef Slaoui as Chair of the Galvani
Board of Directors, effective immediately.
The termination follows the receipt of a letter containing
allegations of sexual harassment and inappropriate conduct towards
an employee of GSK by Dr. Slaoui, which occurred several years ago
when he was an employee of GSK. Upon receipt of the letter, the GSK
Board immediately initiated an investigation with an experienced
law firm to investigate the allegations. The investigation of Dr.
Slaoui's conduct substantiated the allegations and is ongoing.
Dr. Slaoui's behaviours are wholly unacceptable. They represent
an abuse of his leadership position, violate company policies, and
are contrary to the strong values that define GSK's culture. The
company expects everyone at GSK to behave in accordance with its
values, especially its leaders where its standards are the highest.
Sexual harassment and any abuse of leadership position are strictly
prohibited and will not be tolerated.
Christopher Corsico, SVP Development at GSK and a current member
of the Galvani Board, has been appointed as the new Chair of the
Board of Galvani. In addition, Amy Altshul, SVP Legal, R&D and
Global Commercial Franchises at GSK, has also been appointed to the
Board.
GSK's leadership is firmly committed to building a safe and
respectful environment for every employee. The company has
established policies and resources to manage issues related to
workplace safety and conduct while protecting the privacy and
wellbeing of its employees. Over the last few years, it has worked
hard to prioritise and enhance efforts to ensure that all employees
feel respected and included.
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us .
About Galvani Bioelectronics
Galvani Bioelectronics is a medical research company dedicated
to the development of bioelectronic medicines to treat chronic
diseases. Formed through a partnership between two global
healthcare companies, GlaxoSmithKline (GSK) and Verily Life
Sciences (formerly Google Life Sciences), a subsidiary of Alphabet
Inc. in 2016, Galvani Bioelectronics combines life science
knowledge with expertise in software and electronics for clinical
applications.
GSK enquiries:
Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
Madeleine Breckon +44 (0) 20 8047 (London)
5502
Kristen Neese +1 804 217 8147 (Philadelphia)
Kathleen Quinn +1 202 603 5003 (Washington
DC)
Analyst/Investor James Dodwell +44 (0) 20 8047 (London)
enquiries: 2406
Sonya Ghobrial +44 (0) 7392 (Consumer)
784784
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2020 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSEFFELEFSEED
(END) Dow Jones Newswires
March 24, 2021 08:30 ET (12:30 GMT)
Gsk (LSE:GSK)
過去 株価チャート
から 3 2024 まで 4 2024
Gsk (LSE:GSK)
過去 株価チャート
から 4 2023 まで 4 2024